HANDELNINE GLOBAL recalled Rheumacare capsules on December 22, 2025, after discovering lead contamination. The recall affects four bottles of 30 capsules each distributed in New York. Consumers should stop using the product immediately and contact their healthcare provider.
CGMP Deviations: product found to contain lead.
Consumers and healthcare providers should stop using this product immediately. Contact HANDELNINE GLOBAL LLC or your healthcare provider for guidance. Notification method: Press Release
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Rheumacare capsules, sold in 30-count bottles. The affected lots include CAM040, CAL079-N (exp. 06/30/2029), and another with an expiration of 09/30/2028.
The product contains lead, posing serious health risks if ingested. Lead exposure can result in severe health issues, particularly affecting the nervous system.
There have been no specific incidents or injuries reported in connection with this product. However, the presence of lead raises significant health concerns.
Stop using the Rheumacare capsules immediately. Contact HANDELNINE GLOBAL LLC or your healthcare provider for further guidance.
For more information, visit the FDA website or contact HANDELNINE GLOBAL LLC directly. The recall notice is available at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0332-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.